



<b>Title</b>	N-linked glycan in tick-borne encephalitis virus envelope protein affects viral secretion in mammalian cells, but not in tick cells
<b>Author(s)</b>	Yoshii, Kentaro; Yanagihara, Natsumi; Ishizuka, Mariko; Sakai, Mizuki; Kariwa, Hiroaki
<b>Citation</b>	Journal of General Virology, 94, 2249-2258 <a href="https://doi.org/10.1099/vir.0.055269-0">https://doi.org/10.1099/vir.0.055269-0</a>
<b>Issue Date</b>	2013-10
<b>Doc URL</b>	<a href="http://hdl.handle.net/2115/56524">http://hdl.handle.net/2115/56524</a>
<b>Type</b>	article (author version)
<b>Additional Information</b>	There are other files related to this item in HUSCAP. Check the above URL.
<b>File Information</b>	E-glyco paper revised JGV 130703.pdf (article (author version))



[Instructions for use](#)

1       **N-linked glycan in tick-borne encephalitis virus envelope protein affects viral**  
2                               **secretion in mammalian cells, but not in tick cells**

3  
4   Running title: Roles of N-linked glycan in TBEV envelope protein

5   The Content Category: Animal Viruses-Positive-strand RNA

6  
7   Kentaro Yoshii, Natsumi Yanagihara, Mariko Ishizuka, Mizuki Sakai, Hiroaki Kariwa

8  
9   *Laboratory of Public Health, Graduate School of Veterinary Medicine, Hokkaido University,*  
10 *Sapporo, Hokkaido 060-0818, Japan*

11  
12  
13   Corresponding author: Kentaro Yoshii, Ph. D., D.V.M.

14   Postal address: Laboratory of Public Health, Graduate School of Veterinary Medicine, Hokkaido  
15   University, kita-18 nishi-9, kita-ku, Sapporo, Hokkaido 060-0818, Japan

16   Tel/fax: +81-11-706-5213

17   E-mail: [kyoshii@vetmed.hokudai.ac.jp](mailto:kyoshii@vetmed.hokudai.ac.jp)

18  
19   Word count for summary: 188

20   Word count for text: 3992

23

## Abbreviations

24 Baby hamster kidney: BHK

25 brefeldin A: BFA

26 fetal bovine serum: FBS

27 minimal essential medium: MEM

28 monoclonal antibody: MAb

29 parent: pt

30 Tick-borne encephalitis: TBE

31 Tick-borne encephalitis virus: TBEV

32

33

## Summary

34

35

36 Tick-borne encephalitis virus (TBEV) is a zoonotic disease agent that causes severe encephalitis in  
37 humans. The envelope protein E of TBEV has one N-linked glycosylation consensus sequence, but  
38 little is known about the biological function of the N-linked glycan. In this study, the function of  
39 protein E glycosylation was investigated using recombinant TBEV with or without the protein E  
40 N-linked glycan. Virion infectivity was not affected after removing the N-linked glycans using  
41 N-glycosidase F. In mammalian cells, loss of glycosylation affected the conformation of protein E  
42 during secretion, reducing the infectivity of secreted virions. Mice subcutaneously infected with  
43 TBEV lacking protein E glycosylation showed no signs of disease, and viral multiplication in  
44 peripheral organs was reduced relative to that with the parental virus. In contrast, loss of  
45 glycosylation did not affect the secretory process of infectious virions in tick cells. Furthermore,  
46 inhibition of transport to the Golgi apparatus affected TBEV secretion in mammalian cells, but not in  
47 tick cells, indicating that TBEV was secreted through an unidentified pathway after synthesis in  
48 endoplasmic reticulum in tick cells. These results increase our understanding of the molecular  
49 mechanisms of TBEV maturation.

50

51

## Introduction

52

53

54 Tick-borne encephalitis virus (TBEV), a member of the genus *Flavivirus* within the family  
55 *Flaviviridae*, causes tick-borne encephalitis (TBE) in humans. TBE is endemic in Europe, Russia,  
56 and Far-East Asia, including Japan (Blaskovic *et al.*, 1967; Korenberg & Kovalevskii, 1999; Suss,  
57 2011). TBEV can be divided into three subtypes: the Far-Eastern subtype (known as Russian  
58 spring-summer encephalitis virus), the European subtype, and the Siberian subtype (Ecker *et al.*,  
59 1999; Gritsun *et al.*, 1993; Gritsun *et al.*, 1997; Wallner *et al.*, 1995). TBE remains a significant  
60 public health problem in these endemic regions.

61 *Flavivirus* virions are spherical with diameters of 40-50 nm and contain a nucleocapsid and  
62 envelope. The envelope has two viral proteins: the major envelope protein E and the small membrane  
63 protein prM/M. Both proteins are synthesized as part of a polyprotein precursor, which is co- and  
64 post-translationally cleaved into the individual proteins (Lindenbach *et al.*, 2007). Protein E has been  
65 well characterized and mediates viral entry via receptor-mediated endocytosis; in addition, it contains  
66 the major antigenic epitopes that generate protective immune responses (Heinz & Allison, 2003).  
67 The X-ray crystallographic structure of TBEV protein E ectodomain revealed that protein E forms  
68 head-to-tail homodimers that lie parallel to the viral envelope (Rey *et al.*, 1995). In low-pH  
69 conditions, as in endocytic vesicles, the homodimers dissociate, followed by the irreversible  
70 formation of homotrimers (Allison *et al.*, 1995; Stiasny *et al.*, 2001; Stiasny *et al.*, 2002).

71 In the majority of TBEV strains, as in other flaviviruses, protein E contains a conserved N-linked  
72 glycosylation site. It has been reported that the deglycosylation of TBEV by endoglycosidase F does  
73 not impair infectivity (Winkler *et al.*, 1987), but the inhibition of N-linked glycosylation reduces the  
74 secretion of subviral particles from cells expressing the viral proteins prM and E (Goto *et al.*, 2005;  
75 Lorenz *et al.*, 2003). However, as functional analyses of the N-linked glycan on protein E have been  
76 limited to inhibitor treatment or subviral particle systems, little is known regarding the effects of

77 glycosylation on the biological properties of infectious virions, including replication in the tick  
78 vector and pathogenicity in mammals.

79 In this study, we used an infectious TBEV cDNA clone to generate infectious virus containing  
80 protein E with or without the N-linked glycan and directly examined specific phenotypic changes.  
81 Recombinant virus characteristics were examined in mammalian and tick cells as well as in a mouse  
82 model. The results suggest that glycosylation is critical for virus activity in mammals, but not in tick  
83 vectors.

84

85

## Results

86

### 87 **Generation of glycosylation-deficient TBEV**

88 TBEV protein E has one N-linked glycosylation site at amino acids 154-156. To examine the  
89 role of the N-linked glycan, recombinant TBEV expressing protein E that lacks the N-linked glycan,  
90 designated Oshima-IC- $\Delta$ Eg, was constructed using an infectious cDNA clone of Oshima 5-10 TBEV  
91 strain. The asparagine at position 154 of protein E was mutated to glutamine to avoid recognition by  
92 oligosaccharyltransferase (Fig. 1a).

93 To confirm the absence of protein E glycosylation, the nucleotide sequences of the recovered  
94 Oshima-IC- $\Delta$ Eg virus were examined. The introduced mutation was conserved even after 10  
95 passages in BHK cells, and no complementary mutation was found in the coding sequence of any  
96 structural protein.

97 BHK cells were infected with the Oshima-IC-parent (pt) or - $\Delta$ Eg virus, and intracellular protein E  
98 was immunoprecipitated with anti-E monoclonal antibody and analyzed on Western blots and lectin  
99 blots. As shown in Fig. 1b, protein E was detected in immunoprecipitated eluates from cells infected  
100 with either Oshima-IC-pt or - $\Delta$ Eg, but the band for protein E from Oshima-IC- $\Delta$ Eg migrated faster  
101 than that of protein E from Oshima-IC- pt (left panel). Protein E from Oshima-IC-pt was detected by

102 concanavalin A, which binds specifically to high-mannose type N-linked glycans, whereas no band  
103 from cells infected with Oshima-IC- $\Delta$ Eg was detected by concanavalin (Fig. 1b, right panel). These  
104 data indicate that as expected, mutated protein E encoded by Oshima-IC- $\Delta$ Eg virus was not  
105 glycosylated.

106

### 107 **Characteristics of glycosylation-deficient TBEV in mammalian cells**

108 To examine the effect of glycosylation of protein E on viral multiplication, BHK cells were  
109 infected with Oshima-IC-pt or - $\Delta$ Eg at a multiplicity of infection of 0.01. Virus was harvested 12 to  
110 72 h post-infection, and the yield was quantified using a plaque assay. As shown in Fig. 2a, a lower  
111 titer of infectious virus was secreted from cells infected with Oshima-IC- $\Delta$ Eg compared with  
112 Oshima-IC-pt. The plaque size in BHK cells was also smaller for Oshima-IC- $\Delta$ Eg than for  
113 Oshima-IC-pt. These data indicate that glycosylation of protein E affects viral multiplication in BHK  
114 cells.

115 To further characterize the role of glycosylated protein E, the secretion of viral particles was  
116 analyzed. BHK cells were infected with Oshima-IC-pt or - $\Delta$ Eg at a multiplicity of infection of 0.01.  
117 At 48 h post-infection, cell lysates and culture supernatants were prepared, and the levels of  
118 intracellular and secreted protein E were quantified. With the ELISA using polyclonal anti-E  
119 antibodies, the levels of intracellular and secreted protein E were similar between cells infected with  
120 Oshima-IC-pt and with Oshima-IC- $\Delta$ Eg (Fig. 3a). However, based on the ELISA using monoclonal  
121 antibodies specific for protein E conformational epitopes, low levels of protein E were detected in  
122 the culture supernatant of cells infected with Oshima-IC- $\Delta$ Eg compared with Oshima-IC-pt, while  
123 the levels of protein E in cell lysates were similar between the cells infected with Oshima-IC-pt and  
124 with Oshima-IC- $\Delta$ Eg (Fig. 3b). These data show that the lack of protein E glycosylation did not  
125 affect the production or secretion of protein E, but did affect the conformation of secreted protein E.

126 Next, we examined whether the N-linked glycan on protein E of secreted TBEV was involved in

127 viral entry. A total of 100 pfu of Oshima-IC-pt or - $\Delta$ Eg was treated with serially diluted  
128 N-glycosidase F, which cleaves all types of asparagine-bound glycans, and the infectivity of the  
129 resultant virus was analyzed using a plaque assay (Fig. 4). There was no reduction of the virus titer  
130 of Oshima-IC-pt or - $\Delta$ Eg even after treatment with 1 U ml<sup>-1</sup> of N-glycosidase F, indicating that the  
131 cleavage of N-linked glycans on secreted TBEV does not directly affect viral entry processes such as  
132 receptor binding and membrane fusion.

133 These results demonstrate that the conformational structure of protein E during secretion was  
134 affected by the lack of N-linked glycosylation and this reduced virion infectivity, although the  
135 N-linked glycan was not required for viral entry.

136

### 137 **Characteristics of glycosylation-deficient TBEV in tick cells**

138 The effect of the absence of protein E glycosylation was examined in the tick cell line ISE6.  
139 As was observed with BHK cells, protein E of Oshima-IC pt was glycosylated, and protein E of  
140 Oshima-IC- $\Delta$ Eg was not (Fig. 5a). In contrast to BHK cells, ISE6 cells infected with Oshima-IC-pt  
141 and with - $\Delta$ Eg showed no difference in viral multiplication (Fig. 5b) or the amount of secreted  
142 protein E detected using anti-E monoclonal antibodies recognizing protein E conformational epitopes  
143 (Fig. 5c). To investigate whether the different incubation temperature between mammalian cells  
144 (37°C) and tick cells (34°C) affected the stability of the unglycosylated E protein, the virus  
145 multiplication was examined in BHK cells at 34°C. As was observed with the incubation at 37°C  
146 (Fig. 2a), a lower titer of infectious virus was secreted from cells infected with Oshima-IC- $\Delta$ Eg  
147 compared with Oshima-IC-pt in BHK cells at 34°C (supplementary figure 1). These results indicate  
148 that the glycosylation of protein E was not important for viral multiplication or secretion in tick cells.  
149 Flaviviruses are generally thought to bud into the ER of virus-infected cells, followed by transport in  
150 vesicles to the Golgi complex and release by exocytosis via the *trans*-Golgi network (Lindenbach *et*  
151 *al.*, 2007; Mackenzie & Westaway, 2001). To analyze the differences in the roles of TBEV



152 glycosylation in maturation and secretory processes between BHK and ISE6 cells, the effects of  
153 inhibitors of cellular secretory mechanisms were investigated in virus-infected cells. Tunicamycin  
154 was used to inhibit the glycosylation of newly synthesized glycoproteins (Elbein, 1987).  
155 Tunicamycin treatment of BHK cells infected with Oshima-IC-pt or - $\Delta$ Eg reduced the secreted virus  
156 titer, and the reduction was the same for Oshima-IC-pt and - $\Delta$ Eg (Fig. 6a). In ISE6 cells infected  
157 with Oshima-IC-pt or - $\Delta$ Eg, tunicamycin treatment did not reduce the virus titer of Oshima-IC-pt or  
158  $\Delta$ Eg (Fig. 6b). This suggests that the glycosylation of newly synthesized glycoproteins, including  
159 protein E and other glycoproteins such as protein prM or NS1, is important for the maturation and  
160 secretion of TBEV in mammalian BHK cells, but not in tick ISE6 cells. The secretion of infectious  
161 virions was further analyzed using brefeldin A (BFA), which interferes with anterograde transport  
162 from the endoplasmic reticulum to the Golgi apparatus (Fujiwara *et al.*, 1988). BFA treatment of  
163 infected BHK cells significantly reduced the titers of secreted Oshima-IC-pt and - $\Delta$ Eg, whereas BFA  
164 treatment of infected ISE6 cells did not reduce the virus titers (Fig. 6a and b). The glycosylation of  
165 the E proteins of Oshima-IC-pt was examined in ISE6 cells treated with tunicamycin or BFA (Fig.  
166 6c). Tunicamycin treatment inhibited the glycosylation of the E proteins while The E proteins were  
167 still glycosylated after BFA treatment. Thus, the E proteins were naturally glycosylated in ER after  
168 synthesis in ISE6 cells, but it was not necessary for virus secretion. Furthermore, the secretion of  
169 TBEV in tick ISE6 cells was independent of the traditional secretory pathway through the Golgi  
170 apparatus.

171

## 172 **The effect of the glycosylation on the virulence in mice**

173 The effect of glycosylation on pathogenicity was examined in a mouse model. Five-week-old  
174 female C57BL/6J mice were infected subcutaneously with Oshima-IC-pt or - $\Delta$ Eg at  $10^5$  pfu/mouse  
175 and monitored for 28 days (Fig. 7). All mice infected with Oshima-IC-pt showed general signs of  
176 illness such as hunched posture, ruffled fur, and general malaise; one mouse died. However, no mice

177 infected with Oshima-IC-ΔEg showed signs of illness or died.

178 To examine the correlation between disease development and viral replication in organs, viral  
179 loads in the blood, spleen, and brain were compared between mice inoculated with 10<sup>5</sup> pfu of  
180 Oshima-IC-pt and 10<sup>5</sup> pfu of Oshima-IC-ΔEg (Fig. 8). The levels of transient viremia and  
181 multiplication in the spleen were lower in mice infected with Oshima-IC-ΔEg than in those infected  
182 with Oshima-IC-pt. In the brain, the virus was detected from 6 days post-infection in mice infected  
183 with Oshima-IC-pt, while a low titer of virus was detected in only one mouse at 12 days  
184 post-infection with Oshima-IC-ΔEg. These data indicate that the Oshima-IC-ΔEg virus cannot  
185 multiply efficiently in organs, leading to a loss of virulence in mice.

186 Similar high titers of neutralizing antibodies (>320) were observed in mice infected with  
187 Oshima-IC-pt or with Oshima-IC-ΔEg at 12 days post-infection (data not shown), suggesting that  
188 lack of the N-linked glycan on protein E did not affect the induction of neutralizing antibodies.

189

190

## Discussion

191

192 N-linked glycans on viral glycoproteins play important roles in viral multiplication,  
193 immunogenicity, and pathogenicity (Vigerust & Shepherd, 2007). In this study, we used an infectious  
194 TBEV cDNA clone to generate infectious virus with or without protein E N-linked glycan and  
195 investigated specific phenotypic changes in mammalian and tick cells.

196 The defect in protein E glycosylation reduced the secretion of infectious virions in mammalian  
197 cells. In studies of West Nile virus and dengue virus, a defect in glycosylation caused similar  
198 reductions in the release of infectious virions (Hanna *et al.*, 2005; Lee *et al.*, 2010; Li *et al.*, 2006).  
199 Although the total level of secreted protein E remained constant, the conformational structure of  
200 protein E was affected by the lack of glycosylation, resulting in reduced virion infectivity. However,  
201 cleavage of the N-linked glycan after secretion did not affect virion infectivity in mammalian cells.

202 These results indicate that glycosylation is important in retaining the conformational structure of  
203 protein E, which is necessary for virion infectivity during the intracellular secretory process in  
204 mammalian cells. In the endoplasmic reticulum, two homologous resident lectins (calnexin and  
205 calreticulin) bind N-linked core glycans and promote proper folding of glycoproteins (Ellgaard *et al.*,  
206 1999). It is known that the loss of glycosylation alters West Nile virus virion stability at mildly acidic  
207 pHs (Beasley *et al.*, 2005). Defects in protein E glycosylation may affect the proper folding and/or  
208 stability of virions, reducing the infectivity of TBEV in mammalian cells.

209 In the mouse model, protein E glycosylation affected TBEV pathogenicity. TBEV without  
210 protein E glycosylation did not multiply efficiently in peripheral organs, and eventually the virus  
211 could not enter the brain or cause disease in mice. Similarly, reduced neuroinvasiveness due to a  
212 defect in glycosylation was reported in a West Nile virus study (Beasley *et al.*, 2005; Shirato *et al.*,  
213 2004). The mechanism of neuroinvasiveness of TBEV is unclear, but it has been reported that  
214 efficient viral multiplication in peripheral organs is required for TBEV entry into the brain (Mandl,  
215 2005). Reduced infectivity of secreted virions owing to a defect in the glycosylation of protein E, as  
216 observed in cultured cells, is thought to reduce viral multiplication in peripheral organs and to reduce  
217 neuroinvasiveness.

218 TBEV with non-glycosylated protein E could efficiently induce neutralizing antibodies against  
219 TBEV without any clinical symptoms. Also, no revertant or compensatory mutation occurred during  
220 passaging. These data suggest that deletion of the protein E glycosylation site could attenuate TBEV.

221 The lack of protein E glycosylation did not affect the TBEV secretory process in tick cells, unlike  
222 in mammalian cells. Furthermore, the inhibition of transport from the endoplasmic reticulum to the  
223 Golgi apparatus did not affect TBEV multiplication in tick cells. In a previous report, nascent TBEV  
224 particles were observed inside vacuoles, and free nucleocapsids were seen in the cytosol or attached  
225 to the membrane of virus particle-containing vacuoles in tick cells, whereas viral particles appeared  
226 in the endoplasmic reticulum, Golgi apparatus, and secretory pathway in mammalian cells (Senigl *et*

227 *al.*, 2006). Taken together, our data suggest that TBEV secretion in tick cells occurs through an  
228 unidentified mechanism different from the traditional secretory pathway through the Golgi apparatus.

229 Glycosylation-independent virus secretion was observed only in TBEV-infected tick cells.  
230 However, studies of mosquito-borne flavivirus have shown that glycosylation of protein E is  
231 important in both mammalian and mosquito cells (Hanna *et al.*, 2005; Lee *et al.*, 2010). The  
232 difference in virus maturation between arthropod vectors may be associated with the different  
233 ecology of tick-borne and mosquito-borne flaviviruses in their arthropod vectors. Unlike  
234 mosquito-borne flaviviruses, tick-borne flaviviruses establish and maintain a persistent infection  
235 across the various life-stages of the tick vector, through transstadial and transovarial transmission in  
236 nature (Nuttall & Labuda, 2003). In persistent tick infections, viruses are thought to multiply  
237 regardless of the glycosylation of the E proteins. It is possible that because TBEV with glycosylated  
238 protein E has more effective transmission from tick vectors to mammals, it had a selective advantage  
239 during viral evolution.

240 In summary, we generated recombinant TBEV with or without glycosylated protein E. Deletion  
241 of the glycosylation site affected the maturation of TBEV infectious virions in mammalian cells and  
242 reduced TBEV virulence in mice. Our results suggest that TBEV is secreted in a  
243 glycosylation-independent manner in tick cells. Overall, these results increase our understanding of  
244 the molecular mechanism of TBEV maturation and can be applied to attenuate TBEV infection.

245

246

## Methods

247

### *Cells*

249 Baby hamster kidney (BHK) cells were grown at 37°C in Eagle's MEM supplemented with 8%  
250 fetal bovine serum (FBS) and L-glutamine. The ISE6 cell line from *Ixodes scapularis* was grown at  
251 34°C in L-15B medium with 10% FBS and 5% tryptose phosphate broth.

252

253 ***Virus***

254 TBEV Oshima-IC was prepared from infectious cDNA clones of Oshima 5-10 strain (accession  
255 No. AB062003) (Hayasaka *et al.*, 2004), isolated in Hokkaido, Japan in 1995 (Takashima *et al.*,  
256 1997). Standard PCR mutagenesis techniques were used to construct the Oshima-IC-ΔEg virus, in  
257 which nucleotides for the glycosylation site in protein E were mutated as shown in Fig. 1a.

258 RNA was transcribed from the Oshima-IC plasmid using a mMMESSAGE mMACHINE SP6 kit  
259 (Life Technology, Carlsbad, CA, USA) and was transfected into BHK cells using TransIT-mRNA  
260 (Mirus Bio, Madison, WI, USA), as described previously (Yoshii *et al.*, 2011; Yoshii *et al.*, 2004).

261

262 ***Reagents***

263 N-glycosidase F (Roche, Basel, Switzerland) was used to cleave protein E N-linked glycan in  
264 infectious virions. A total of 100 TBEV plaque forming units (pfu) were treated with serially diluted  
265 N-glycosidase F (10 μU ml<sup>-1</sup> to 1 U ml<sup>-1</sup>) for 1 h at 37°C, and the virus was titrated.

266 The effects of tunicamycin (Sigma-Aldrich, St. Louis, MO, USA), and brefeldin A (Wako, Osaka,  
267 Japan) on the secretion of viral particles were examined. At the indicated times post-infection,  
268 virus-infected cells were treated with 2 μg ml<sup>-1</sup> of tunicamycin, or 2 μg ml<sup>-1</sup> of brefeldin A, and the  
269 secreted virus was titrated after 12 h.

270

271 ***Immunoprecipitation, SDS-PAGE, immunoblotting and lectin-blotting***

272 BHK cells were infected with Oshima-IC-parent (pt) or ΔEg. At 48 h post-infection, the cells  
273 were lysed with 1% Triton X-100 in 10 mM TBS, incubated on ice for 20 min, and centrifuged  
274 (16,000 × g, 20 min). The supernatant (excluding the nuclear fraction) was precleared on protein  
275 G-Sepharose beads (Amersham Pharmacia Biotech) for 2 h at 4°C. The precleared lysates were  
276 precipitated with protein G-Sepharose beads with mouse monoclonal anti-E antibody 1H4 (Komoro

277 *et al.*, 2000) for 2 h at 4°C. Immune complexes were collected by centrifugation (10,000 × g, 10 s)  
278 and washed four times with 1% Triton X-100 in 10 mM TBS. Protein samples were electrophoresed  
279 through 12% (w/v) polyacrylamide-SDS gels. Protein bands were transferred onto PVDF membranes  
280 and incubated with 1% (w/v) gelatin in 25 mM TBS containing 0.01% (v/v) Tween 20. After a wash  
281 with 25 mM TBS containing 0.01% (v/v) Tween 20, the membranes were reacted with rabbit  
282 polyclonal anti-E antibodies (Yoshii *et al.*, 2004) or biotinylated lectin concanavalin A (J-Oil Mills,  
283 Tokyo, Japan), followed by alkaline phosphatase-conjugated secondary antibody or streptavidin  
284 (Jackson ImmunoResearch, West Grove, PA, USA), respectively. Protein bands were visualized  
285 using an alkaline phosphatase detection kit (Merck, Darmstadt, Germany) according to the  
286 manufacturer's protocol.

287

## 288 ***ELISA***

289 The TBEV protein E was detected by sandwich-ELISA using a set of anti-E polyclonal  
290 antibodies or monoclonal antibodies recognizing conformational epitopes of protein E. Briefly, to  
291 prepare samples, virus-infected cells were lysed with 1% (v/v) Triton X-100 in 10 mM TBS, and the  
292 supernatants were treated with 1% Triton X-100.

293 For ELISA using a set of anti-E polyclonal antibodies, Triton X-100-solubilized samples were  
294 added to 96-well microtiter plates coated with rabbit polyclonal anti-E antibodies. After blocking  
295 with 3% (w/v) bovine serum albumin, protein E was detected by incubation with TBEV-infected  
296 mouse serum and horseradish peroxidase-conjugated anti-mouse IgG antibody (Jackson  
297 ImmunoResearch).

298 For ELISA using monoclonal antibodies recognizing conformational epitopes of protein E,  
299 samples were added to wells coated with mouse monoclonal anti-E antibody 1H4, previously  
300 blocked with 3% (w/v) bovine serum albumin. Protein E was detected by incubation with  
301 biotinylated monoclonal antibody (MAb) 4H8 and peroxidase-conjugated streptavidin (Sigma).

302 Peroxidase activity was detected by adding *o*-phenylenediamine dihydrochloride (Sigma) in the  
303 presence of 0.03% (v/v) H<sub>2</sub>O<sub>2</sub>, and the absorbance was measured at 450 nm.

304

305

### 306 ***Virulence in mouse***

307 Viruses were inoculated subcutaneously into 5-week-old female C57BL/6J mice (Charles River  
308 Laboratories International, Inc., Wilmington, MA, USA). Morbidity was defined as >10% weight  
309 loss. The mice were monitored for 28 days post-infection determine the survival curve and mortality  
310 rate. To analyze the virus distribution in tissues, the serum, brains, and spleens were collected from  
311 mice 3, 6, 9, and 12 days post-infection. The organs were weighed individually, homogenized, and  
312 prepared as 10% suspensions in PBS (w/v) containing 10% FBS. The suspensions were clarified by  
313 centrifugation (4,000 rpm for 5 min, 4°C), and the supernatants were titrated using plaque assays in  
314 BHK cells.

315

### 316 ***Titration and neutralization test***

317 For titration, cell monolayers prepared in 12-well plates were incubated with serial dilutions of  
318 the virus for 1 h, overlaid with minimal medium containing 2% FBS and 1.5% carboxymethyl  
319 cellulose, and incubated for 5 days. After incubation, the cells were fixed and stained with 0.25%  
320 crystal violet in 10% buffered formalin. Plaques were counted and expressed as pfu ml<sup>-1</sup>. For the  
321 neutralization test, serum samples that induced a 50% reduction in Oshima-IC-pt plaque formation  
322 were examined.

323

324

## **Acknowledgement**

325

326 This work was supported by Grants-in-Aid for Scientific Research (22780268 and 21405035)

327 and the Global COE Program from the Ministry of Education, Culture, Sports, Sciences and  
328 Technology of Japan, and Health Sciences Grants for Research on Emerging and Re-emerging  
329 Infectious Disease from the Ministry of Health, Labour and Welfare of Japan.

330  
331 **Author Disclosure Statement**

332  
333 No competing financial interests exist in this paper.

334  
335 **References**

- 336  
337 **Allison, S. L., Schalich, J., Stiasny, K., Mandl, C. W., Kunz, C. & Heinz, F. X. (1995).** Oligomeric  
338 rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH. *J Virol*  
339 **69**, 695-700.
- 340 **Beasley, D. W., Whiteman, M. C., Zhang, S., Huang, C. Y., Schneider, B. S., Smith, D. R., Gromowski, G.**  
341 **D., Higgs, S., Kinney, R. M. & Barrett, A. D. (2005).** Envelope protein glycosylation status  
342 influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. *J Virol* **79**,  
343 8339-8347.
- 344 **Blaskovic, D., Pucekova, G., Kubinyi, L., Stupalova, S. & Oravcova, V. (1967).** An epidemiological study of  
345 tick-borne encephalitis in the Tribec region: 1953-63. *Bull World Health Organ* **36**, Suppl 1:89-94.
- 346 **Ecker, M., Allison, S. L., Meixner, T. & Heinz, F. X. (1999).** Sequence analysis and genetic classification of  
347 tick-borne encephalitis viruses from Europe and Asia. *The Journal of general virology* **80**, 179-185.
- 348 **Elbein, A. D. (1987).** Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains.  
349 *Annual review of biochemistry* **56**, 497-534.
- 350 **Ellgaard, L., Molinari, M. & Helenius, A. (1999).** Setting the standards: quality control in the secretory  
351 pathway. *Science* **286**, 1882-1888.
- 352 **Fujiwara, T., Oda, K., Yokota, S., Takatsuki, A. & Ikehara, Y. (1988).** Brefeldin A causes disassembly of the  
353 Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum. *The Journal*  
354 *of biological chemistry* **263**, 18545-18552.
- 355 **Goto, A., Yoshii, K., Obara, M., Ueki, T., Mizutani, T., Kariwa, H. & Takashima, I. (2005).** Role of the  
356 N-linked glycans of the prM and E envelope proteins in tick-borne encephalitis virus particle  
357 secretion. *Vaccine* **23**, 3043-3052.



358 **Gritsun, T. S., Frolova, T. V., Pogodina, V. V., Lashkevich, V. A., Venugopal, K. & Gould, E. A. (1993).**  
359 Nucleotide and deduced amino acid sequence of the envelope gene of the Vasilchenko strain of  
360 TBE virus; comparison with other flaviviruses. *Virus research* **27**, 201-209.

361 **Gritsun, T. S., Venugopal, K., Zanotto, P. M., Mikhailov, M. V., Sall, A. A., Holmes, E. C., Polkinghorne, I.,**  
362 **Frolova, T. V., Pogodina, V. V., Lashkevich, V. A. & Gould, E. A. (1997).** Complete sequence of two  
363 tick-borne flaviviruses isolated from Siberia and the UK: analysis and significance of the 5' and  
364 3'-UTRs. *Virus research* **49**, 27-39.

365 **Hanna, S. L., Pierson, T. C., Sanchez, M. D., Ahmed, A. A., Murtadha, M. M. & Doms, R. W. (2005).**  
366 N-linked glycosylation of west Nile virus envelope proteins influences particle assembly and  
367 infectivity. *J Virol* **79**, 13262-13274.

368 **Hayasaka, D., Gritsun, T. S., Yoshii, K., Ueki, T., Goto, A., Mizutani, T., Kariwa, H., Iwasaki, T., Gould, E.**  
369 **A. & Takashima, I. (2004).** Amino acid changes responsible for attenuation of virus neurovirulence  
370 in an infectious cDNA clone of the Oshima strain of tick-borne encephalitis virus. *The Journal of*  
371 *general virology* **85**, 1007-1018.

372 **Heinz, F. X. & Allison, S. L. (2003).** Flavivirus structure and membrane fusion. *Advances in virus research*  
373 **59**, 63-97.

374 **Komoro, K., Hayasaka, D., Mizutani, T., Kariwa, H. & Takashima, I. (2000).** Characterization of  
375 monoclonal antibodies against Hokkaido strain tick-borne encephalitis virus. *Microbiology and*  
376 *immunology* **44**, 533-536.

377 **Korenberg, E. I. & Kovalevskii, Y. V. (1999).** Main features of tick-borne encephalitis eco-epidemiology in  
378 Russia. *Zentralbl Bakteriol* **289**, 525-539.

379 **Lee, E., Leang, S. K., Davidson, A. & Lobigs, M. (2010).** Both E protein glycans adversely affect dengue  
380 virus infectivity but are beneficial for virion release. *J Virol* **84**, 5171-5180.

381 **Li, J., Bhuvanankantham, R., Howe, J. & Ng, M. L. (2006).** The glycosylation site in the envelope protein of  
382 West Nile virus (Sarafend) plays an important role in replication and maturation processes. *The*  
383 *Journal of general virology* **87**, 613-622.

384 **Lindenbach, B. D., Thiel, H. J. & Rice, C. M. (2007).** *Flaviviridae: The viruses and their replication*. In  
385 *Fields virology*, 5th edn, pp. 1101-1152. Edited by D. M. Knipe & P. M. Howley. Philadelphia:  
386 Lippincott Williams & Wilkins.

387 **Lorenz, I. C., Kartenbeck, J., Mezzacasa, A., Allison, S. L., Heinz, F. X. & Helenius, A. (2003).**  
388 Intracellular assembly and secretion of recombinant subviral particles from tick-borne  
389 encephalitis virus. *J Virol* **77**, 4370-4382.

390 **Mackenzie, J. M. & Westaway, E. G. (2001).** Assembly and maturation of the flavivirus Kunjin virus  
391 appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively.  
392 *J Virol* **75**, 10787-10799.

393 **Mandl, C. W. (2005).** Steps of the tick-borne encephalitis virus replication cycle that affect  
394 neuropathogenesis. *Virus research* **111**, 161-174.

- 395 **Nuttall, P. A. & Labuda, M. (2003).** Dynamics of infection in tick vectors and at the tick-host interface.  
396 *Advances in virus research* **60**, 233-272.
- 397 **Rey, F. A., Heinz, F. X., Mandl, C., Kunz, C. & Harrison, S. C. (1995).** The envelope glycoprotein from  
398 tick-borne encephalitis virus at 2 Å resolution. *Nature* **375**, 291-298.
- 399 **Senigl, F., Grubhoffer, L. & Kopecky, J. (2006).** Differences in maturation of tick-borne encephalitis virus  
400 in mammalian and tick cell line. *Intervirology* **49**, 239-248.
- 401 **Shirato, K., Miyoshi, H., Goto, A., Ako, Y., Ueki, T., Kariwa, H. & Takashima, I. (2004).** Viral envelope  
402 protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain  
403 of West Nile virus. *The Journal of general virology* **85**, 3637-3645.
- 404 **Stiasny, K., Allison, S. L., Mandl, C. W. & Heinz, F. X. (2001).** Role of metastability and acidic pH in  
405 membrane fusion by tick-borne encephalitis virus. *J Virol* **75**, 7392-7398.
- 406 **Stiasny, K., Allison, S. L., Schalich, J. & Heinz, F. X. (2002).** Membrane interactions of the tick-borne  
407 encephalitis virus fusion protein E at low pH. *J Virol* **76**, 3784-3790.
- 408 **Suss, J. (2011).** Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and  
409 Asia-an overview. *Ticks and tick-borne diseases* **2**, 2-15.
- 410 **Takashima, I., Morita, K., Chiba, M., Hayasaka, D., Sato, T., Takezawa, C., Igarashi, A., Kariwa, H.,  
411 Yoshimatsu, K., Arikawa, J. & Hashimoto, N. (1997).** A case of tick-borne encephalitis in Japan  
412 and isolation of the the virus. *Journal of clinical microbiology* **35**, 1943-1947.
- 413 **Vigerust, D. J. & Shepherd, V. L. (2007).** Virus glycosylation: role in virulence and immune interactions.  
414 *Trends in microbiology* **15**, 211-218.
- 415 **Wallner, G., Mandl, C. W., Kunz, C. & Heinz, F. X. (1995).** The flavivirus 3'-noncoding region: extensive  
416 size heterogeneity independent of evolutionary relationships among strains of tick-borne  
417 encephalitis virus. *Virology* **213**, 169-178.
- 418 **Winkler, G., Heinz, F. X. & Kunz, C. (1987).** Studies on the glycosylation of flavivirus E proteins and the  
419 role of carbohydrate in antigenic structure. *Virology* **159**, 237-243.
- 420 **Yoshii, K., Igarashi, M., Ito, K., Kariwa, H., Holbrook, M. R. & Takashima, I. (2011).** Construction of an  
421 infectious cDNA clone for Omsk hemorrhagic fever virus, and characterization of mutations in  
422 NS2A and NS5. *Virus research* **155**, 61-68.
- 423 **Yoshii, K., Konno, A., Goto, A., Nio, J., Obara, M., Ueki, T., Hayasaka, D., Mizutani, T., Kariwa, H. &  
424 Takashima, I. (2004).** Single point mutation in tick-borne encephalitis virus prM protein induces a  
425 reduction of virus particle secretion. *The Journal of general virology* **85**, 3049-3058.

426

427

428 **Figure legends**

429 **Fig.1. Construction of recombinant TBEV containing protein E with or without its N-linked**  
430 **glycan.**

431 (a) Schematic of recombinant TBEV. The symbol Y shows the predicted glycans on TBEV envelope  
432 proteins. The amino acid sequence of the protein E glycosylation site is expanded at the bottom of  
433 the figure for Oshima-IC-pt. In Oshima-IC- $\Delta$ Eg, the glycosylation site of protein E contains a  
434 mutation (bold).

435 (B) Confirmation of protein E glycosylation in recombinant viruses. BHK cells were infected with  
436 Oshima-IC-pt (pt) or Oshima-IC- $\Delta$ Eg ( $\Delta$ Eg). At 48 h post-infection, intracellular protein E was  
437 immunoprecipitated using anti-E antibodies. Precipitated protein E was detected using anti-E  
438 antibodies (left panel) or concanavalin A (right panel).

439

440 **Fig. 2. Effect of protein E glycosylation on viral replication in BHK cells.**

441 (a) BHK cells were infected with Oshima-IC-pt or  $\Delta$ Eg at a multiplicity of infection of 0.01. At each  
442 time point, medium was harvested, and virus titers were measured using plaque assays in BHK cells.

443 (b) Plaques of Oshima-IC-pt and  $\Delta$ Eg in BHK cells at 4 days post-infection.

444

445 **Fig. 3. Effect of protein E glycosylation on synthesis and secretion of protein E in BHK cells.**

446 BHK cells were infected with Oshima-IC-pt (pt) or Oshima-IC- $\Delta$ Eg ( $\Delta$ Eg) at a multiplicity of  
447 infection of 0.01. At 48 h post-infection, cell lysates and culture supernatants were harvested. Levels  
448 of intracellular and secreted protein E were measured by ELISA using anti-E polyclonal (a) or  
449 monoclonal antibodies recognizing conformational epitopes of protein E (b). The percentage of  
450 protein E was calculated from the calibration curve for the amount of pt in each experiment.

451

452 **Fig. 4. Infectivity of TBEV after cleavage of the N-linked glycan on the virion.**

453 A total of 100 pfu of Oshima-IC-pt (pt) or Oshima-IC- $\Delta$ Eg ( $\Delta$ Eg) was treated with serially diluted  
454 N-glycosidase F, and the virus titers were determined using plaque assays in BHK cells. The pfu of  
455 mock-treated virus was set at 100%.

456

457 **Fig. 5. Effect of protein E glycosylation on viral replication in ISE6 cells.**

458 ISE6 cells were infected with Oshima-IC-pt or Oshima-IC- $\Delta$ Eg at a multiplicity of infection of 0.01.

459 (a) Intracellular protein E was immunoprecipitated using anti-E antibodies. Precipitated protein E  
460 was detected using anti-E antibodies (upper panel) or concanavalin A (lower panel). (b) At each time  
461 point, the medium was harvested, and virus titers were determined using plaque assays in BHK cells.  
462 (c) At 48 h post-infection, cell lysates and culture supernatants were harvested. The levels of  
463 intracellular and secreted protein E were measured by ELISA using an anti-E monoclonal antibody  
464 recognizing conformational epitopes of protein E. The percentage of protein E was calculated from  
465 the calibration curve for the amount of pt in each experiment.

466

467 **Fig. 6. The effect of inhibitors on the secretion of infectious virus.**

468 BHK (a) and ISE6 (b) cells were infected with Oshima-IC-pt or Oshima-IC- $\Delta$ Eg at a multiplicity of  
469 infection of 0.01. At 24 h post-infection for BHK and 72 h for ISE6 cells, the medium was replaced  
470 with fresh medium containing 2  $\mu$ g ml<sup>-1</sup> of tunicamycin (Tuni), 2  $\mu$ g ml<sup>-1</sup> of brefeldin A (BFA), or  
471 DMSO (Mock). After 12 h, the medium was harvested, and virus titers were determined using plaque  
472 assays in BHK cells. (c) After the treatment of tunicamycin (Tuni), brefeldin A (BFA) or DMSO  
473 (Mock), intracellular protein E in ISE6 cells infected with Oshima-IC-pt was immunoprecipitated  
474 using anti-E antibodies. Precipitated protein E was detected using anti-E antibodies (left panel) or  
475 concanavalin A (right panel). NC: uninfected negative control cell.

476

477 **Fig. 7. Survival rate (a), morbidity (b), and weight change (c) following infection with TBEV.**

478 B6 mice were subcutaneously infected with  $10^5$  pfu of Oshima-IC-pt (closed circles) or  
479 Oshima-IC- $\Delta$ Eg (open squares) and monitored for 28 days. Mouse morbidity was estimated based on  
480  $>10\%$  weight loss. The average daily weight change was calculated based on the ratio of the daily  
481 weight to the weight at day 0. Error bars represent standard deviations.

482

483 **Fig. 8. Virus replication in organs.**


484 Mice were subcutaneously infected with  $10^5$  pfu of Oshima-IC-pt (closed circles) or Oshima-IC- $\Delta$ Eg  
485 (open squares). At the indicated days after infection, virus titers in blood (**a**), spleen (**b**), and brain (**c**)  
486 were determined using plaque assays. Error bars represent standard deviations ( $n = 3$ ).

487


# Figure 1

a


TBEV Oshima-IC-pt



TBEV Oshima-IC-ΔEg



b




**Fig.1. Construction of recombinant TBEV containing protein E with or without its N-linked glycan.**


a. Schematic of recombinant TBEV. The symbol Y shows the predicted glycans on TBEV envelope proteins. The amino acid sequence of the protein E glycosylation site is expanded at the bottom of the figure for Oshima-IC-pt. In Oshima-IC-ΔEg, the glycosylation site of protein E contains a mutation (bold). b. Confirmation of protein E glycosylation in recombinant viruses. BHK cells were infected with Oshima-IC-pt (pt) or Oshima-IC-ΔEg (ΔEg). At 48 h post-infection, intracellular protein E was immunoprecipitated using anti-E antibodies. Precipitated protein E was detected using anti-E antibodies (left panel) or concanavalin A (right panel).

# Figure 2

## a. growth curve



## b. plaque




**Fig. 2. Effect of protein E glycosylation on viral replication in BHK cells.**


(a) BHK cells were infected with Oshima-IC-pt or ΔEg at a multiplicity of infection of 0.01. At each time point, medium was harvested, and virus titers were measured using plaque assays in BHK cells. (b) Plaques of Oshima-IC-pt and ΔEg in BHK cells at 4 days post-infection.

# Figure 3

## a. ELISA using anti-E pAb




## b. ELISA using MAb recognizing conformational epitope of E



**Fig. 3. Effect of protein E glycosylation on synthesis and secretion of protein E in BHK cells.** BHK cells were infected with Oshima-IC-pt (pt) or Oshima-IC- $\Delta$ Eg ( $\Delta$ Eg) at a multiplicity of infection of 0.01. At 48 h post-infection, cell lysates and culture supernatants were harvested. Levels of intracellular and secreted protein E were measured by ELISA using anti-E polyclonal (a) or monoclonal antibodies recognizing conformational epitopes of protein E (b). The percentage of protein E was calculated from the calibration curve for the amount of pt in each experiment.




**Figure 4**



**Fig. 4. Infectivity of TBEV after cleavage of the N-linked glycan on the virion.**

A total of 100 pfu of Oshima-IC-pt (pt) or Oshima-IC-ΔEg (ΔEg) was treated with serially diluted N-glycosidase F, and the virus titers were determined using plaque assays in BHK cells. The pfu of mock-treated virus was set at 100%.

# Figure 5





**Fig. 5. Effect of protein E glycosylation on viral replication in ISE6 cells.**

ISE6 cells were infected with Oshima-IC-pt or Oshima-IC-ΔEg at a multiplicity of infection of 0.01.

(a) Intracellular protein E was immunoprecipitated using anti-E antibodies. Precipitated protein E was detected using anti-E antibodies (upper panel) or concanavalin A (lower panel). (b) At each time point, the medium was harvested, and virus titers were determined using plaque assays in BHK cells. (c) At 48 h post-infection, cell lysates and culture supernatants were harvested. The levels of intracellular and secreted protein E were measured by ELISA using an anti-E monoclonal antibody recognizing conformational epitopes of protein E. The percentage of protein E was calculated from the calibration curve for the amount of pt in each experiment.

# Figure 6




**Fig. 6. The effect of inhibitors on the secretion of infectious virus.**


BHK (a) and ISE6 (b) cells were infected with Oshima-IC-pt or Oshima-IC-ΔEg at a multiplicity of infection of 0.01. At 24 h post-infection for BHK and 72 h for ISE6 cells, the medium was replaced with fresh medium containing  $2 \mu\text{g ml}^{-1}$  of tunicamycin (Tuni),  $2 \mu\text{g ml}^{-1}$  of brefeldin A (BFA), or DMSO (Mock). After 12 h, the medium was harvested, and virus titers were determined using plaque assays in BHK cells. (c) After the treatment of tunicamycin (Tuni), brefeldin A (BFA) or DMSO (Mock), intracellular protein E in ISE6 cells infected with Oshima-IC-pt was immunoprecipitated using anti-E antibodies. Precipitated protein E was detected using anti-E antibodies (left panel) or concanavalin A (right panel). NC: uninfected negative control cell.

# Figure 7


a. Survival rate



b. Morbidity




c. Weight change



**Fig. 7. Survival rate (a), morbidity (b), and weight change (c) following infection with TBEV.** B6 mice were subcutaneously infected with  $10^5$  pfu of Oshima-IC-pt (closed circles) or Oshima-IC- $\Delta$ Eg (open squares) and monitored for 28 days. Mouse morbidity was estimated based on  $>10\%$  weight loss. The average daily weight change was calculated based on the ratio of the daily weight to the weight at day 0. Error bars represent standard deviations.

# Figure 8



**Fig. 8. Virus replication in organs.**

Mice were subcutaneously infected with 10<sup>5</sup> pfu of Oshima-IC-pt (closed circles) or Oshima-IC-ΔEg (open squares). At the indicated days after infection, virus titers in blood (a), spleen (b), and brain (c) were determined using plaque assays. Error bars represent standard deviations (n = 3).